GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (STU:7CA) » Definitions » Debt-to-EBITDA

Camurus AB (STU:7CA) Debt-to-EBITDA : 0.02 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Camurus AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Camurus AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.9 Mil. Camurus AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.6 Mil. Camurus AB's annualized EBITDA for the quarter that ended in Dec. 2024 was €66.1 Mil. Camurus AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Camurus AB's Debt-to-EBITDA or its related term are showing as below:

STU:7CA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.26   Med: -0.02   Max: 0.3
Current: 0.03

During the past 13 years, the highest Debt-to-EBITDA Ratio of Camurus AB was 0.30. The lowest was -0.26. And the median was -0.02.

STU:7CA's Debt-to-EBITDA is ranked better than
93.14% of 277 companies
in the Biotechnology industry
Industry Median: 1.54 vs STU:7CA: 0.03

Camurus AB Debt-to-EBITDA Historical Data

The historical data trend for Camurus AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Debt-to-EBITDA Chart

Camurus AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.26 0.30 0.04 0.03

Camurus AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 0.06 0.05 0.03 0.02

Competitive Comparison of Camurus AB's Debt-to-EBITDA

For the Biotechnology subindustry, Camurus AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Camurus AB's Debt-to-EBITDA falls into.


;
;

Camurus AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Camurus AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.861 + 0.621) / 49.401
=0.03

Camurus AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.861 + 0.621) / 66.088
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Camurus AB  (STU:7CA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Camurus AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Camurus AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB Business Description

Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.

Camurus AB Headlines

No Headlines